The biodistribution, metabolism, cellular targeting, and gene expression of a nonviral peptide DNA gene delivery system was examined.
INTRODUCTION
Nonviral gene delivery relies on the use of carrier molecules to bind plasmid DNA and mediate cellspecific uptake of the DNA carrier complex. [1] [2] [3] [4] [5] [6] The efficiency of an intravenously dosed nonviral gene delivery dosage form is dependent on the DNA carrier complex to overcome obstacles that prevent it from arriving at the target cell. Depending on the size and charge of a DNA complex, it may be opsonized and entrapped in the capillary beds of the lung or may be phagocytosed by liver Kupffer cells or spleen macrophages. 7 The DNA carrier complex must possess sufficient serum stability to remain intact during circulation since premature dissociation exposes unprotected DNA resulting in rapid metabolism by serum endonucleases. 8 Once endocytosed by target cells, the DNA carrier complex must also escape degradative pathways and target the nucleus. 7 In the absence of a carrier molecule, 60-70% of i.v. dosed plasmid DNA is taken up by scavenger receptors on liver Kupffer cells. 8, 9 To facilitate selective targeting to hepatocytes, ligands for the asialoglycoprotein receptor (ASGP-R) have been incorporated into carrier molecules. 1, 2, [10] [11] [12] [13] [14] [15] [16] [17] [18] One of the first carriers was a conjugate of high molecular weight (HMW) polylysine 440 covalently linked to asialoorosomucoid (ASOR), 11 a glycoprotein possessing terminal galactose residues on its N-glycans. Following i.v. dosing, ASOR-polylysine DNA condensates were also rapidly taken up by liver and then slowly eliminated with t 1 /2 of 1.3 h due to the metabolic protection provided by polylysine. 11 To further extend the liver half-life of DNA and the duration of gene expression, Chowdhury et al. performed partial hepatectomy following the delivery of ASOR-polylysine DNA condensates to rats. 12 Since lysosomal trafficking is dramatically decreased following partial hepatectomy, the rate of DNA metabolism was also decreased resulting in the recovery of 9% of the dose in the liver after 24 h.
Refinements in carrier design have resulted in the replacement of ASOR-polylysine with lactosylated and galactosylated polylysine. 13, 14 Perales et al. examined the ability of a galactosylated polylysine 100 to mediate liver targeting and reported the PCR detection of DNA in the liver for 32 days but did not attempt to determine cell-type specific targeting.
14 Recent studies by Hashida et al. utilized galactosylated polylysine 100 as a carrier to establish that 70% of the liver targeted DNA resides in hepatocytes. 15, 16 Opsonization of the DNA carrier complex could be minimized by controlling the polylysine DNA stoichiometry to create electronegative DNA complexes; however, this approach is unlikely to allow DNA targeting to peripheral sites since electronegative DNA condensates are also taken up nonspecifically by liver Kupffer cells. 15, 16 An alternative approach to increase the resistance of polylysine DNA condensates to opsonization is to incorporate polyethylene glycol (PEG)-polylysine to shield the surface charge of DNA condensates. [19] [20] [21] Thus far, only one study has examined the utility of PEGylated ASOR-polylysine 100 as a DNA carrier for i.v. dosed formulations and found that PEG decreased the aggregation of DNA condensates but failed to influence the in vivo biodistribution. 22 It is now clear that optimizing a gene delivery formulation will require deriving correlations between the physico-chemical properties of the DNA carrier complex and in vivo parameters such as biodistribution, cell-type targeting specificity, metabolism and elimination, and gene expression. 22 To do so requires the complete synthetic control over the design of carrier molecules which can only be achieved by reducing their molecular weight. Consequently, the utility of derivatized HMW polylysine as a condensing agent to optimize gene expression is inadequate since it leads to increased heterogeneity and does not allow precise control over the location or stoichiometry of ligand or PEG attachment. 22 Properly designed LMW DNA carriers will not only eliminate heterogeneity but can also be systematically optimized to reduce or eliminate toxicity. 23 Therefore, it is essential to determine if low molecular weight (LMW) carriers can be designed to replace HMW polylysine conjugates as i.v. dosed nonviral gene delivery systems.
To test this hypothesis, we propose the use of two well-defined LMW carriers that can be admixed to allow the ratio of targeting ligand and PEG on DNA condensates to be systematically optimized. The LMW carriers used in the present study are derivatives of a synthetic peptide, CysTrp-Lys 18 (CWK 18 ), which forms small (<100 nm) DNA condensates capable of mediating efficient nonspecific gene transfer to cells in culture. [24] [25] [26] To endow the delivery system with targeting specificity, a natural triantennary N-glycan ligand has been covalently attached to the side chain of cysteine in CWK 18 resulting in a triantennary glycopeptide (Tri-CWK 18 ) that binds to the ASGP-R with a nM dissociation constant. 27, 28 We have also recently reported the synthesis and formulation of PEG-CWK 18 DNA condensates that mask the surface charge of DNA condensates and reduce nonspecific interactions with cells. 29 Additionally, the stability of LMW peptide DNA condensates has been greatly improved by use of glutaraldehyde as a crosslinking agent that both slows DNA metabolism and alters the in vitro transient gene expression profile. 30 Here we report the in vivo analysis of glutaraldehyde crosslinked DNA co-condensates prepared with Tri-CWK 18 and PEG-CWK 18 to systematically optimize DNA targeting to hepatocytes via the ASGP-R. The relationships derived between physiochemical properties and biodistribution provide insight into formulation parameters to improve the level of transient gene expression in vivo.
MATERIALS AND METHODS

Sodium
125 iodide was purchased from Dupont NEN (Boston, MA). Heparin, D-mannitol, bovine serum albumin, Hepes, collagenase from Clostridium histolyticum type IV (lot number: 47H6865), carbonyl iron, 70% glutaraldehyde, 2,2Ј-azion-bis(3-ethylbenzthiaxoline-6-sulfonic acid (ABTS), Tween 20, anti-human ␣-1-antitryp-sin IgG from goat and rabbit, and human ␣-1-antitrypsin were purchased from Sigma (St. Louis, MO). Zeta probe cationic membranes were purchased from Bio-Rad (Hercules, CA). Agarose was purchased from Gibco-BRL (Gaithersburg, MD). Methoxy-PEG-vinylsulfone (5,000 Da) was purchased from Fluka (Ronkonkoma, NY). Ketamine hydrochloride was purchased from Fort Dodge Laboratories (Fort Dodge, IA). Xylazine hydrochloride was purchased from Miles Inc. (Shawnee Mission, KS). Silastic catheters (0.305 mm inner diameter × 0.635 mm outer diameter) were purchased from Baxter (Obetz, OH). ICR mice (30-35 g ) were purchased from Harlan (Indianapolis, IN) and housed in cages located in a limited access area maintaining a 12-h light-dark cycle and controlled temperature (26-28°C). ␤-Galactosidase from bovine testes (EC 3.2.1.23) and anti-rabbit IgG-peroxidase from goat were purchased from Boehringer Mannheim (Indianapolis, IN). Ultrapure 100 and tip100, DNA purification columns were purchased from Qiagen (Santa Clarita, CA). Analytical and semipreparative HPLC columns were purchased from Vydac (Hesperia, CA).
Radiolabeling Plasmid DNA
Endotoxin-free plasmid DNA encoding human ␣-1-antitrypsin (hAAT) driven by a cytomegalovirus promoter (pCMVhAAT) 31 was purified from Escherichia coli using a Qiagen ultrapure column according to the manufacturers instructions. Plasmid DNA was radiolabeled with 125 I as described previously resulting in supercoiled and circular DNA with specific activity of 200 nCi/g.
32
Glycopeptide and PEG-Peptide Synthesis CWK 18 was prepared and alkylated with iodoacetic acid to form AlkCWK 18 as described previously. 24 A triantennary N-glycan was purified from bovine fetuin as the Boc-tyrosine derivative. 33 The oligosaccharide was converted to an iodoacetylated tyrosinamide oligosaccharide and then reacted with CWK 18 to form Tri-CWK 18 .
27
Agalactosyl Tri-CWK 18 was prepared by treating 400 nmol of Tri-CWK 18 with 4 mU of ␤-galactosidase in 5 mM citrate phosphate, pH 4.3, at 37°C for 24 h. The glycopeptide was purified by injecting 50 nmol on an analytical RP-HPLC column (0.47 × 25 cm) eluted at 1 mL/min with 0.1% TFA and a gradient of acetonitrile from 5% to 25% over 30 min. The product peak eluting at 20 min was collected and freeze-dried. The complete removal of galactose from the purified glycopeptide was confirmed using ES-MS, 1 H NMR, and monosaccharide composition analysis. 27 Polyethylene glycol vinyl sulfone (PEG-VS) was reacted with CWK 18 to prepare PEG-CWK 18 -which was purified and characterized as reported previously. 18 ) to form 40 nmol/mL admixtures used to condense DNA as described above.
Glutaraldehyde crosslinked DNA condensates were formed by adding 60 or 150 nmol of glutaraldehyde (6 or 15 mol eq of glutaraldehdye per mol of CWK 18 ) to 500 L of 50 g/mL preformed DNA condensates, followed by reaction for 24 h at 4°C. 30 The stability of crosslinked DNA condensates were evaluated by adjusting 200 L aliquots (10 g DNA) to 0.3, 0.5, 1.0, and 1.5 M sodium chloride (normalized to 300 L) followed by sonication for 30 s with a 100 W Microson XL-2000 ultrasonic probe homogenizer (Kontes, Vineland, NJ) with a vibrational amplitude of 5 to fragment uncondensed DNA. 30 DNA condensates (0.5 g) were digested for 12 h at 37°C with 40 g of trypsin and then electrophoresed on an agarose gel and visualized by ethidium bromide staining.
Crosslinked Tri-CWK 18 /PEG-CWK 18 DNA cocondensates (50 g in 1 mL) were dialyzed for 75 h in a fixed volume dialyzer against a 100,000 MWCO membrane to remove unbound peptides. DNA co-condensates (25 g) in the retentate were then hydrolyzed in 4 N hydrochloric acid at 100°C for 5 h to release glucosamine from Tri-CWK 18 . The samples were dried and reconstituted in 200 L of water, and a 40-L aliquot was analyzed by high-pH anion-exchange chromatography relative to a glucosamine standard. 34 Comparison of the glucosamine recovered before and after dialysis allowed quantification of the percent of Tri-CWK 18 incorporated into crosslinked DNA cocondensates.
Pharmacokinetic Analysis of DNA Condensates.
Mice were anesthetized by i.p. injection of ketamine hydrochloride (100 mg/kg) and xylazine hydrochloride (10 mg/kg) and then underwent a dual cannulation of the right and left jugular veins. An i.v. dose of 125 I-DNA (5 g in 50 L of HBM, 1.2 Ci) or 125 I-DNA condensate (5 g) was administered via the left catheter, and blood samples were drawn from the right catheter at 1, 3, 6, 10, 15, 20, 30, 40, and 60 min, then replaced with 10 L of normal saline. The amount of radioactivity in each blood time point was quantified by direct ␥-counting followed by extraction of the DNA and analysis by gel electrophoresis as described below. Blood time points (10 L) were digested with proteinase K (500 L of 0.5 mg/mL proteinase K in 100 mM sodium chloride, 1% SDS, and 50 mM Tris-HCl, pH 8.0) for 12 h at 37°C. DNA was extracted with 500 L of phenol/ chloroform/isoamyl alcohol (24:25:1) and then precipitated with 1 mL of ethanol and centrifuged at 13,000g for 15 min. The DNA pellet was airdried, dissolved in 10 L of Tris-EDTA buffer, and ␥-counted, and then the entire sample was loaded and electrophoresed for 1 h at 70 V on an 1% agarose gel. The gel was dried on a zeta probe membrane and autoradiographed on a Phosphor Imager (Molecular Devices, Sunnyvale CA) following a 15-h exposure.
Biodistribution Analysis of 125 I-DNA and 125 I-DNA Condensates
Mice were anesthetized, and a single catheter was placed in the right jugular vein.
125 I-DNA (2.5 g in 50 L of HBM, 0.6 Ci) or 125 I-DNA condensates were i.v. dosed followed by vein ligation. After 5, 15, 30, 60, or 120 min, mice were sacrificed by cervical dislocation and the major organs (liver, lung, spleen, stomach, kidney, heart, large intestine, and small intestine) were harvested, rinsed with saline, and weighed. The radioactivity in each organ was determined by direct ␥-counting and expressed as the targeting efficiency, defined as the percent of the dose in the target organ.
Isolation of Hepatocytes and Kupffer Cells
Mice were i.v. dosed in the tail vein with 20 mg of carbonyl iron in 0.2 mL of saline. After 45 min, mice were anesthetized and a single catheter was inserted into the right jugular vein and used to dose 125 I-DNA or 125 I-DNA condensates (2.5 g DNA in 50 L, 0.6 Ci in HBM). Following 30 min of biodistribution, the portal vein was cannulated and used to administer 0.2 mL of heparin (100 U/mL) followed immediately by the perfusion buffers. The liver was first perfused at 5 mL/min for 2 min with oxygenated (95% oxygen, 5% carbon dioxide) preperfusion buffer (calcium-and magnesium-free Hepes solution, pH 7.45, 37°C), and then at 3 mL/min for an additional 3 min. The liver was digested by perfusion with oxygenated Seglen's Buffer (pH 7.45, 37°C) containing 0.058% (w/v) collagenase type IV at 3 mL/min for 16-20 min. At the start of the perfusion, the vena cava and aorta were cut, and at the completion, the liver was excised, placed in a Petri dish (4°C), and cut into small pieces. Cells were dislodged and dispersed in ice-cold Hank's solution containing 10 mM Hepes, pH 7.45, 0.1% BSA, and then incubated at 37°C for 20 min with shaking (30 rev/ min). The dispersed cells were passaged through a 73-m mesh filter then transferred to a 35-mL glass tube. The iron-filled Kupffer cells were attracted to the wall of the tube with a magnet while other cells were decanted off. The procedure was repeated three times, and the Kupffer cells were combined and resuspended in 0.8 mL of Hank's Hepes Buffer. The remaining cell suspension was centrifuged at 50g for 1 min and the supernatant was discarded. The pelleted hepatocytes were washed twice with ice-cold Hank'sHepes buffer followed by centrifuging at 50g for 1 min. The hepatocytes were re-suspended in 2 mL of Hank's-Hepes buffer and the cell number and viability were determined by the trypan blue dyeexclusion method. The amount of radioactivity associated with each cell fraction was determined by ␥-counting.
In Vivo Gene Expression
Mice were dosed in the tail vein by infusing 1 mL of HBM containing either 50 g of plasmid DNA (30 mice), 50 g of crosslinked agalactosyl-Tri-CWK 18 /PEG-CWK 18 (10:90) DNA co-condensates (30 mice) or 50 g of crosslinked Tri-CWK 18 /PEG-CWK 18 (10:90) DNA co-condensates (60 mice). Blood (1 mL) was collected via the jugular artery from 3-6 mice per day for 10 days after dosing. The blood was allowed to clot at room temperature and centrifuged at 13,000g for 15 min, and the serum that was collected was stored frozen at −20°C until assayed by ELISA.
A modified double-antibody sandwich ELISA was used to determine the magnitude of hAAT gene expression. 35 After each incubation, the wells were washed three times with phosphatebuffered saline, pH 7.4, containing 0.05% Tween 20 (PBS-Tween). The goat anti-hAAT primary antibody was diluted 1:1000 in 0.1 M sodium bicarbonate, pH 9.6, and 100 L was added to each well and incubated overnight at 4°C. Nonspecific binding was blocked with 100 L of 5 w/v % nonfat dry milk in PBS incubated for 1 h at 37°C. Mouse serum samples (100 L) or hAAT primary standards added to mouse serum were added to each well and allowed to bind for 2 h at 37°C. The rabbit anti-hAAT secondary antibody (diluted 1: 1000 in PBS-Tween) was added (100 L) to each well followed by incubation at 37°C for 2 h. Antirabbit peroxidase conjugated antibody (diluted 1: 1000 in PBS-Tween) was added (100 L) and allowed to bind for 2 h at room temperature. Finally, substrate solution (100 L of 1 mg/mL ABTS in 0.2 M sodium phosphate, pH 7.6, with 0.003% hydrogen peroxide) was added and incubated at RT for 30 min prior to reading the absorbance at 415 nm on a Bio-Rad 550 microplate reader. The amount of hAAT expressed was determined from a standard curve prepared from the addition of hAAT to mouse serum.
RESULTS
Tri-CWK 18 , PEG-CWK 18 , and AlkCWK 18 were prepared and used as LMW DNA carrier molecules ( Figure 1 ). The terminal galactose residues of Tri-CWK 18 were removed with ␤-galactosidase to create agalactosyl-Tri-CWK 18 as a negative control for ASGP-R recognition.
1 H NMR, ES-MS, and monosaccharide compositional analysis each confirmed the removal of all three terminal galactose residues. 27 Biodistribution analysis of radioiodinated Tri-CWK 18 and agalactosyl-Tri-CWK 18 established the liver as the major target site, resulting in a 30-min liver targeting efficiency (percent of dose in the target organ) of 1.3 ± 0.1% for agalactosyl-Tri-CWK 18 versus 52.9 ± 3.5% determined for Tri-CWK 18 (not shown). These results are in close agreement with similar biodistribution studies on triantennary tyrosinamide oligosaccharides, 36, 37 establishing the requirement for galactose to mediate ASGP-R recognition of Tri-CWK 18 .
Plasmid DNA was radiolabeled with 125 I to generate a DNA probe to determine the fate of i.v. dosed gene delivery formulations. Pharmacokinetic analysis of uncondensed plasmid DNA established its rapid removal from the circulation following i.v. dosing with less than 30% of the dose remaining in the blood after 1 min ( Figure  2A ). Electrophoretic analysis of the DNA remaining in blood established it was completely fragmented within 6 min ( Figure 2AЈ ) indicating that the majority of the pharmacokinetic profile represented elimination of metabolites. The analysis of AlkCWK 18 and Tri-CWK 18 DNA condensates established a similar profile of rapid elimination ( Figure 2B,C) and formation of metabolites within 6 min ( Figure 2BЈ ,CЈ) suggesting that neither AlkCWK 18 nor Tri-CWK 18 significantly protected DNA from endonucleases either in the serum or tissues.
Biodistribution analysis of i.v. dosed plasmid DNA, AlkCWK 18 , and Tri-CWK 18 DNA condensates established the liver as the major target site at 5 min for all three formulations, resulting in a targeting efficiency of 60% for plasmid DNA, 48% for AlkCWK 18 DNA condensates, and 57% for Tri-CWK 18 DNA condensates ( Figure 3A ) with all other organs possessing <7% of the 125 I-DNA dose. A similar biodistribution profile was observed at 15 and 30 min for each formulation with proportional decreases in the liver targeting over time without significant increases in the distribution to other tissues ( Figure 3B,C) .
The biodistribution time was extended to 2 h to examine the half-life of 125 I-DNA in the liver. Plasmid DNA was rapidly eliminated from the liver with a t 1 /2 of 0.61 h, resulting in only 7% of the radioactive dose remaining in the liver after 2 h ( Figure 4A ). AlkCWK 18 DNA condensates and Tri-CWK 18 DNA condensates were also rapidly eliminated from the liver with a similar t 1 /2 of 0.8 and 0.63 h, respectively ( Figure 4B,C) . These results suggested that either AlkCWK 18 and Tri-CWK 18 DNA condensates dissociate during circulation or they fail to significantly protect DNA from metabolism in the liver.
If stable during circulation, AlkCWK 18 and Tri-CWK 18 DNA condensates would likely produce altered cell-type specific targeting in the liver relative to plasmid DNA. Therefore, the cellular distribution of 125 I-DNA in the liver was investigated by separating hepatocytes and Kupffer cells following collagenase perfusion. Plasmid DNA distributed with 65% to Kupffer cells and 35% to hepatocytes while AlkCWK 18 DNA condensates produced a nearly identical distribution with 68% associated with Kupffer cells and 32% with hepatocytes ( Table 1) . These data supported a hypothesis involving the rapid serum dissociation of AlkCWK 18 DNA condensates with subsequent biodistribution of plasmid DNA. Analysis of Tri-CWK 18 DNA condensates established a slight improvement in the cell-type specific targeting with 55% distributed to Kupffer cells and 45% to hepatocytes, providing some evidence that Tri-CWK 18 DNA condensates are at least partially stable during circulation and facilitate some recognition by the ASGP-R ( Table 1) .
The short half-life of DNA condensates in the liver also suggested that little or no metabolic protection was afforded using LMW DNA carriers ( Figure 4A-C) . To determine if this was only true of LMW carriers, the biodistribution of a HMW polylysine 1007 DNA condensate was analyzed since it is less likely to dissociate during circulation and is reportedly more resistant to in vitro DNA metabolism than AlkCWK 18 DNA condensates. 30 Even though polylysine 1007 and AlkCWK 18 DNA condensates were similar in particle size and zeta potential (Table 2) , polylysine 1007 DNA condensates biodistributed with only 25% associated with the liver and 25% in lung after 5 min. The longer liver elimination t 1 /2 of 2.8 h implied that polylysine 1007 DNA condensates were intact in the liver (Table 1) . Presumably, polylysine 1007 DNA condensates are rapidly opsonized during circulation due to their electropositive surface charge (Table 2) , causing their biodistribution to the lung. The fact that there was minimal lung targeting associated with AlkCWK 18 DNA condensates supports the hypothesis that these dissociate during circulation. Notably, 54% of the polylysine 1007 125 I-DNA condensate recovered in the liver was associated with Kupffer cells, whereas 46% was with hepatocytes (Table 1 ). This result established that both electronegative plasmid DNA and electropositive HMW polylysine DNA condensates produce a similar nonspecific cell-type distribution when 18 DNA condensates (C) (5 g) were dosed i.v. in triplicate mice and 10-L blood samples were drawn at times ranging from 1 to 60 min. Direct ␥-counting of blood time points resulted in the pharmacokinetic profiles plotted as the mean ± standard deviation versus sampling time in A-C. Following extraction from blood time points, DNA samples were resolved by agarose gel electrophoresis and detected by autoradiography to establish the DNA morphology as supercoiled (sc), circular (cir), or fragmented as illustrated in AЈ, BЈ, and CЈ. The results indicate that plasmid DNA and condensed DNA is quickly cleared from the circulation and metabolized into DNA fragments within 6 min following i.v. dosing. taken up by the liver. Collectively, these results supported the hypothesis that the primary difference between polylysine 1007 and AlkCWK 18 DNA condensates was their stability during circulation.
To overcome the short elimination half-life of LMW peptide DNA condensates, glutaraldehyde was used to crosslink and stabilize DNA condensates as reported previously. 30 Note that crosslinking Tri-CWK 18 or PEG-CWK 18 DNA condensates required higher glutaraldehyde concentrations (6-15 mol eq) to achieve equivalent stability to AlkCWK 18 DNA condensates (4 mol eq) as determined by the salt sonication gel electrophoresis assay. 30 The crosslinked DNA condensates were utilized without removing residual glutaraldehyde and afford stabilized DNA condensates that maintained particle size for up to 1 week when stored at 4°C.
Crosslinked AlkCWK 18 DNA condensates were similar in size (50 nm) and charge (+34 mV) to HMW polylysine DNA condensates (Table 2) . However when dosed i.v., 70% of the dose accumulated in the lung at 2 h with less then 1% re- covered from the liver. These results further support the hypothesis that uncrosslinked AlkCWK 18 DNA condensates dissociate during circulation, and that once stabilized by crosslinking, the electropositive surface charge results in rapid opsonization and significant lung targeting.
Crosslinked Tri-CWK 18 DNA condensates also possessed a mean diameter of 56 nm and a slightly reduced zeta potential of +20 mV (Table  2) . However when dosed i.v., 59% of crosslinked Tri-CWK 18 DNA condensates targeted the liver at 5 min followed by elimination with a t 1 /2 of 2.6 h, such that 38% of the dose remained in the liver at 2 h ( Figure 4D ). In contrast to crosslinked AlkCWK 18 DNA condensates, crosslinked Tri-CWK 18 DNA condensates avoided targeting to the lung, suggesting that the triantennary oligosaccharide is sufficient to block opsonization of DNA condensates in the blood. Despite the decrease in the liver elimination rate afforded by crosslinking, the cell-type specific targeting was only modestly improved over uncrosslinked Tri-CWK 18 DNA condensates, resulting in 45% targeting to Kupffer cells and 55% to hepatocytes (Table 1) . These results suggested that the remaining positive charge on crosslinked Tri-CWK 18 DNA condensates may be responsible for the nonspecific targeting to Kupffer cells.
A further reduction in the surface charge of DNA condensates may improve the hepatocyte targeting of Tri-CWK 18 DNA condensates by masking their detection by Kupffer cells. Other gene delivery systems accomplish this by precisely titrating HMW carriers with DNA to form condensates having neutral or negative charge. 15, 16, 22 This strategy is not suitable for the LMW carriers since these require crosslinking to remain intact during circulation, and glutaraldehyde crosslinking requires the presence of excess amine groups on DNA for the formation of Schiffbases. 30 An alternative approach is to mask the surface charge of DNA condensates by incorporating PEG-CWK 18 as previously demonstrated by the formation of PEG-CWK 18 /AlkCWK 18 DNA cocondensates. 29 In this study, PEG-CWK 18 and Tri-CWK 18 were admixed and used to prepare DNA co-condensates as shown in Scheme 1. Tri-CWK 18 /PEG-CWK 18 (50 mol %) DNA co-condensates crosslinked with 15 mol eq of glutaraldehyde were 39 nm in diameter and possessed a zeta potential of +5 mV ( Table 2 ). The ratio of Tri-CWK 18 and PEG-CWK 18 bound to DNA in cocondensates was nearly the same as the admix ratio used to condense DNA as revealed by glu- (10 6 )/Kupffer cells (10 5 ). e Calculated as the percent of cpm in either hepatocytes (10 6 ) or Kupffer cells (10 5 ) over total. f Calculated by ln C 0 ‫ס‬ ln C − kt, t 1/2 ‫ס‬ 0.693/k, assuming first-order kinetics from C max .
cosamine analysis which recovered 96% of the Tri-CWK 18 after prolonged dialysis.
Biodistribution analysis of crosslinked Tri-CWK 18 /PEG-CWK 18 DNA co-condensates resulted in a lag in the liver accumulation of radioactivity that peaked at 61% of the dose at 30 min followed by elimination with a t 1 /2 of 2.1 h resulting in 37% remaining in the liver at 2 h ( Figure  4E ). As predicted, the cell-type specific targeting was dramatically improved with only 20% recovered in the Kupffer cells and 80% in hepatocytes, demonstrating the ability of PEG to mask the surface charge of DNA condensates reducing their nonspecific recognition by liver Kupffer cells.
As a negative control, crosslinked agalactosylTri-CWK 18 /PEG-CWK 18 DNA co-condensates were studied. The liver targeting efficiency was similar to otherwise identical DNA condensates containing Tri-CWK 18 , also resulting in an elimination t 1 /2 of 2.5 h ( Figure 4F ). However, only 55% of the liver targeted DNA was recovered in hepatocytes whereas 45% was found in Kupffer cells, establishing that terminal galactose residues on Tri-CWK 18 are responsible for approximately 25% of the cell-type specific targeting of these DNA condensates.
To determine if the admix ratio could be adjusted to further reduce the amount of Tri-CWK 18 without compromising target site selectivity, biodistribution studies were conducted using a 10:90 admix ratio of crosslinked Tri-CWK 18 /PEG-CWK 18 DNA co-condensates. The liver targeting efficiency reached approximately 61% in 15 min and remained at 57% at 30 min and was then eliminated with a t 1 /2 of 3.6 h, resulting in 44% of the dose in the liver after 2 h ( Figure 4G ). A control, in which agalactosyl-Tri-CWK 18 was substituted for Tri-CWK 18 had a similar liver biodistribution profile with an elimination t 1 /2 of 2.4 h ( Figure 4H) . As was the case for condensates prepared with 50:50 Tri-CWK 18 /PEG-CWK 18 , 80% of the 125 I-DNA was recovered in hepatocytes when using Tri-CWK 18 whereas only 54% was in hepatocytes using agalactosyl-Tri-CWK 18 . Further experiments established that as little as 2 mol % of Tri-CWK 18 admixed with 98% PEG-CWK 18 formed crosslinked DNA co-condensates that mediated a targeting efficiency of 53% in the liver at 30 min of which 80% was recovered in hepatocytes (Table 1) .
A final set of control studies examined the bio- Figure 4I ). Interestingly, 53% of the liver target DNA was recovered in the hepatocyte fraction whereas the remaining 47% was associated with Kupffer cells (Table 1) . These results indicated that even without incorporating a targeting ligand, crosslinked PEG-CWK 18 DNA condensates are still taken up through a nonspecific process by both Kupffer cells and hepatocytes.
Crosslinked DNA co-condensates were also evaluated for their ability to mediate hAAT expression in vivo. A 1-mL dose containing 50 g of DNA condensates was administered via slow infusion into the tail vein of mice. The large dosing volume was used to ensure a small particle size since concentrations above 100 g/mL result in larger particles. 29 However, when PEG-CWK 18 is included at 98 mol % of the admix ratio, small particles (<100 nm) can be maintained at high concentrations (2 mg/mL), 29 which will allow the dosing volume to be reduced and systematically explored in future studies. Even when dosing 50 g of DNA, biodistribution studies using an 125 I-DNA tracer established a 2-h liver targeting efficiency of 36% with 73% recovered in hepatocytes, suggesting the 50-g dose did not saturate the ASGP-R ( Table 1) .
Analysis of the transient gene expression profile of hAAT after i.v. dosing 50 g of crosslinked Tri-CWK 18 /PEG-CWK 18 (10:90) DNA co-condensates demonstrated a peak in the expression at day 7 at 6 ng/mL that returned to a baseline levels by day 9 ( Figure 5 ). Similar analysis of agalactosyl-Tri-CWK 18 /PEG-CWK 18 (10:90) DNA cocondensates established the complete lack of gene expression which was an identical result to a control using plasmid DNA ( Figure 5 ).
DISCUSSION
The development of a therapeutically useful nonviral gene delivery formulation will require systematic optimization of the DNA carrier complex to achieve maximum targeting selectivity and gene expression. The present study has attempted to establish correlations between the composition of the carrier components bound to plasmid DNA and the targeting efficiency to hepatocytes in mice with the aim of determining if LMW carriers can be used to mediate gene transfer in vivo. No other previous studies have reported the in vivo use of LMW peptides as substitute DNA carriers for HMW conjugates despite the importance of reducing the molecular weight and heterogeneity of these biomolecules in order to avoid unwanted side effects.
The results clearly indicate that a LMW carrier by itself is not sufficient to mediate gene targeting of an i.v. dosed DNA formulation. This is not obvious from a preliminary investigation since 58% of Tri-CWK 18 DNA condensates targeted the liver after 5 min of biodistribution. However, when evaluated in light of control experiments demonstrating that plasmid DNA and AlkCWK 18 DNA condensates also target the liver with very similar efficiency, it becomes clear that plasmid DNA is released upon dissociation of LMW carriers during circulation.
A surprising result was that crosslinked Tri-CWK 18 DNA condensates are not sufficient to achieve maximum hepatocyte targeting even though the oligosaccharide used is a potent ligand for the ASGP-R, possessing a million-fold greater affinity than galactose. 28 Despite the presence of approximately 700 copies of the triantennary li- Each data point represents the mean and standard error for 3-6 mice. Comparison of hAAT expression levels on day 7 to levels on day 1 or day 10 established statistical significance (P < 0.025). gand per 6.9 kb plasmid, the electropositive charge of crosslinked Tri-CWK 18 DNA condensates is apparently still detected by Kupffer cells. It is also interesting to note that crosslinked Tri-CWK 18 DNA condensates did have significantly altered biodistribution in comparison to HMW polylysine and crosslinked AlkCWK 18 DNA condensates of comparable size and charge. The presence of the triantennary N-glycan allowed these DNA condensates to avoid lung targeting, presumably by blocking opsonization in the serum.
Only after incorporating both PEG-CWK 18 and Tri-CWK 18 into DNA condensates could specific recognition by hepatocytes be achieved. This closely correlated with a decreased zeta potential, indicating that PEG functioned to block Kupffer cell recognition by masking the surface charge of Tri-CWK 18 DNA condensates. The masking was equally efficient with either 50, 90, or 98 mol % PEG-CWK 18 as indicated by the hepatocyte targeting efficiency. Moreover, this data indicates that attachment of as few as 14 copies (2 mol %) of the triantennary oligosaccharide to a plasmid is sufficient to mediate specific recognition by the ASGP-R and that the surface bound PEG does not sterically block ASGP-R recognition of Tri-CWK 18 . Using this high-affinity ligand, the ASGP-R was able to bind DNA co-condensates in the dosing range of 2.5-50 g delivered via tail vein without a significant reduction in target selectivity for hepatocytes ( Table 1) .
The use of LMW carriers also necessitates the use of crosslinking agents to stabilize DNA carrier condensates. The advantages of this approach are that LMW carriers can be synthesized, purified, and structurally characterized, eliminating uncertainty over the stoichiometry or attachment site of ligands to the backbone peptide. Two or potentially more LMW carriers can be combined and used to condense DNA to form cocondensates. Since each LMW carrier contains an identical cationic peptide, they incorporate into DNA co-condensates according to their admix ratio 29 allowing systematic optimization of the amount of ligand or PEG bound to DNA condensates.
The disadvantage of LMW carriers is the necessity for molecular crosslinking. Although this stabilizes DNA condensates to metabolism, 30 the use of glutaraldehyde results in an overall lower level of in vitro gene expression which appears also to be true of in vivo expression. Likewise, crosslinked LMW carriers may resemble HMW carriers once they are released inside the cell and exhibit similar toxicity. To circumvent these problems, other methods under development could serve to both transiently stabilize LMW DNA carrier condensates and simultaneously enhance the gene expression level. [38] [39] [40] As a proof of principle we have demonstrated that specific targeting to hepatocytes requires the use of crosslinked Tri-CWK 18 /PEG-CWK 18 DNA condensates. The metabolic stabilization afforded by crosslinking is apparent by comparison of the liver t 1 /2 of uncrosslinked and crosslinked Tri-CWK 18 DNA condensates (Figure 4) . Since retention of DNA in the target site is an important prerequisite to sustaining transient gene expression, the degree of crosslinking may be an adjustable parameter to control the time of onset or duration of gene expression.
Incorporating PEG-CWK 18 into DNA condensates resulted in a lag of 40-60 min in the peak accumulation of 125 I-DNA in the liver ( Figure 4E -I). Since this lag is not apparent when using uncrosslinked DNA condensates ( Figure 4A-C) , it is unlikely the result of re-distribution and uptake of metabolized 125 I-DNA. It is more likely due to a slower recognition of the DNA condensate by either the asialoglycoprotein receptor when incorporating Tri-CWK 18 or by the Kupffer cell scavenger receptor when substituted with agalactosyl-Tri-CWK 18 .
Comparison of the transient gene expression of optimized LMW dosage forms with and without ligand established a dependency on galactose. The maximal gene expression occurring at day 7 is mostly likely due to the slow release of crosslinked DNA co-condensates. Although the serum levels of hAAT are low compared to hepatic portal vein dosed viral vector delivery systems, 41 there is no reference data regarding the levels of liver expression of hAAT following i.v. dosing of a viral delivery systems.
In conclusion, the results presented demonstrate that it is possible to use a combination of LMW carrier molecules to achieve cell-type specific gene delivery and transient gene expression in mouse liver. The information from this study should provide a foundation from which to pursue DNA targeting to organs other than the liver. Further studies will be needed to optimize LMW carriers to increase the transient gene expression levels. This will likely involve the application of crosslinking strategies designed to release DNA inside the target cells. 37, 38 
